Company’s line of differentiated generics offers producers proven efficacy and value.
Norbrook® North America announces it has expanded its portfolio of swine products available to help pork producers and veterinarians enhance the well-being of their animals and improve their operations. Recently, the company added Cefenil® RTU to its growing portfolio of generic products for use in swine.
Cefenil RTU joins a growing list of Norbrook products available to the swine industry, including 300 PRO LA® (oxytetracycline), Enroflox® 100, Flunixin Injection, Oxytetracycline 200, Noromycin® 300 LA, Norocillin® Injection and Noromectin® (Ivermectin). These products offer producers and veterinarians cost-effective alternatives to pioneer products.
In addition, Norbrook recently assigned Megan Schnur, DVM, to lead the company’s technical service efforts in swine. Dr. Schnur has worked with swine producers and veterinarians for the last six years and has extensive experience in swine health and production. “The swine market is critically important to Norbrook. Our swine products and services provide effective and economical solutions to many diseases that pork producers and veterinarians deal with on a regular basis, and that impact production and profitability,” Dr. Schnur explains. “We will continue to offer additional innovative, highly effective solutions to customers, along with our technical veterinary expertise, for years to come.”
In 2020, Norbrook marked 50 years of bringing new, innovative and differentiated animal health products to the global marketplace. As a Top 20 global animal health company, it has a long history of investing in research and development, manufacturing, operations and distribution channels that help deliver cost-effective solutions to customers worldwide.
For more information about Norbrook’s growing line of swine products and technical services that help enhance the health and well-being of livestock, visit Norbrook.com.
